EGFR and non-small cell lung carcinoma: Treatment with cetuximab, an epidermal growth factor receptor inhibitor, in combination with platinum-based chemotherapy can only be offered to specific NSCLC patients with EGFR-positive tumors, which also increases the risk of febrile neutropenia.